Patents by Inventor John M. Luk

John M. Luk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230348556
    Abstract: A non-viral vector, comprising, from 5? to 3?, flanked by two transposon terminal inverted repeats, an inducible promoter, a first coding region comprising a specific combination of genes whose expression is localized to a tumor microenviorment and their function being mediators of CAR persistence and anti-tumor mechanisms to stimulate or enhance a patient anti-tumor response; a second promoter and coding region for expressing one or more artificial immunosurveillance chimeric antigen receptors (AI-CAR), and a truncated CD20 or truncated EGFR safety target. A polycistronic mRNA comprised of a specific combination of transiently expressed anti-tumor mechanisms designed to stimulate a patient anti-tumor response the same as an AI-CAR vector.
    Type: Application
    Filed: February 21, 2020
    Publication date: November 2, 2023
    Inventors: Donald E. Staunton, John M. Luk, John M. Harlan, David Kin Jin
  • Publication number: 20220185882
    Abstract: The application provides non-viral vector, comprising an artificial immunosurveillance chimeric antigen receptor (AI-CAR) expression cassette flanked by two transposons or viral terminal repeats (IR), wherein the AI-CAR expression cassette comprises an inducible gene expression unit and a CAR expression unit.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 16, 2022
    Inventors: Donald E. Staunton, John M. Luk, John M. Harlan
  • Patent number: 6287817
    Abstract: A protein conjugate consisting of antibody directed at the pIgR and A1AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides us with the ability to deliver a therapeutic protein directly to the apical surface of the epithelium, by targeting the pIgR with an appropriate ligand. Thus, the highest concentration of the antiprotease will be at the apical surface, where it can do the greatest good in accelerating the inflammatory response.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: September 11, 2001
    Assignee: Case Western Reserve University
    Inventors: Pamela B. Davis, Thomas Ferkol, Elizabeth Eckman, John Schreiber, John M. Luk
  • Patent number: 6072041
    Abstract: A protein conjugate consisting of antibody directed at the pIgR and A.sub.1 AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides us with the ability to deliver a therapeutic protein directly to the apical surface of the epithelium, by targeting the pIgR with an appropriate ligand. Thus, the highest concentration of the antiprotease will be at the apical surface, where it can do the greatest good in accelerating the inflammatory response.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: June 6, 2000
    Assignee: Case Western Reserve University
    Inventors: Pamela B. Davis, Thomas Ferkol, Elizabeth Eckman, John Schreiber, John M. Luk